Trial Profile
Development of a Model to Predict Progression Free Survival After Treatment With Erlotinib in E3503
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 24 May 2017 New trial record